ENOblock inhibited the pathology of diet-induced obesity by acting as a transcriptional repressor of master regulators of lipid homeostasis (Srebp-1a and Srebp-1c), gluconeogenesis (Pck-1), and inflammation (TNF-α and IL-6). Here, TNF is linked to obesity due to melanocortin 4 receptor deficiency.